Comparison of 2-year mortality according to obesity in stabilized patients with type 2 diabetes mellitus after acute myocardial infarction: results from the DIAMOND prospective cohort registry by Ki-Bum Won et al.
Won et al. Cardiovasc Diabetol  (2015) 14:141 
DOI 10.1186/s12933-015-0305-1
ORIGINAL INVESTIGATION
Comparison of 2-year mortality 
according to obesity in stabilized patients 
with type 2 diabetes mellitus after acute 
myocardial infarction: results from the 
DIAMOND prospective cohort registry
Ki‑Bum Won1, Seung‑Ho Hur1, Yun‑Kyeong Cho1, Hyuck‑Jun Yoon1, Chang‑Wook Nam1, Kwon‑Bae Kim1, 
Jang‑Ho Bae2, Dong‑Ju Choi3, Young‑Keun Ahn4, Jong‑Seon Park5, Hyo‑Soo Kim6*, Rak‑Kyeong Choi7, 
Donghoon Choi8, Joon‑Hong Kim9, Kyoo‑Rok Han10, Hun‑Sik Park11, So‑Yeon Choi12, Jung‑Han Yoon13, 
Hyeon‑Cheol Kwon14, Seung‑Un Rha15, Kyung‑Kuk Hwang16, Do‑Sun Lim17, Kyung‑Tae Jung18, Seok‑Kyu Oh19, 
Jae‑Hwan Lee20, Eun‑Seok Shin21 and Kee‑Sik Kim22
Abstract 
Background: After acute myocardial infarction (AMI), the replicated phenomenon of obesity paradox, i.e., obesity 
appearing to be associated with increased survival, has not been evaluated in stabilized (i.e., without clinical events 
within 1 month post AMI) Asian patients with diabetes mellitus (DM).
Methods: Among 1192 patients in the DIabetic Acute Myocardial InfarctiON Disease (DIAMOND) Korean multicenter 
registry between April 2010 and June 2012, 2‑year cardiac and all‑cause death were compared according to obesity 
(body mass index ≥25 kg/m2) in 1125 stabilized DM patients.
Results: Compared with non‑obese DM patients (62 % of AMI patients), obese DM patients had: higher incidence 
of dyslipidemia (31 vs. 24 %, P < 0.01); lower incidence of chronic kidney disease (26 vs. 33 %) (P < 0.01); higher left 
ventricular ejection fraction after AMI (53 ± 11 vs. 50 ± 12 %, P < 0.001); and lower 2‑year cardiac and all‑cause 
death occurrence (0.7 vs. 3.6 % and 1.9 vs. 5.2 %, both P < 0.01) and cumulative incidence in Kaplan–Meier analysis 
(P < 0.005, respectively). Likewise, both univariate and multivariate Cox hazard regression analyses adjusted for the 
respective confounders showed that obesity was associated with decreased risk of both cardiac [HR, 0.18 (95 % CI 
0.06–0.60), P = 0.005; and 0.24 (0.07–0.78), P = 0.018, respectively] and all‑cause death [0.34 (0.16–0.73), P = 0.005; 
and 0.44 (0.20–0.95), P = 0.038].
Conclusions: In a Korean population of stabilized DM patients after AMI, non‑obese patients appear to have higher 
cardiac and all‑cause mortality compared with obese patients after adjusting for confounding factors.
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Background
Obesity is strongly associated with an increased risk of 
numerous comorbidities and mortality in the general 
population [1–3]. In particular, obese subjects are more 
prone to be affected by cardiovascular (CV) events than 
non-obese subjects [4]. However, obesity appearing to 
be associated with improved survival has been reported 
after major CV events such as acute myocardial infarc-
tion (AMI) [5–9].
It is well established that diabetes mellitus (DM) is 
a major risk factor for CV morbidity and mortality [10, 
11]. Previous studies have reported that diabetic patients 
have an increased risk for mortality after AMI [12, 13]. 
However, there is a paucity of data on the association 
between obesity and mortality in diabetic patients after 
the event of AMI; identifying this association may be 
more important in the Asian population because of the 
explicitly different features of DM in Asia [14–16]. In 
addition, it is necessary to evaluate this association in 
stabilized (i.e., without clinical events within 1  month) 
patients after AMI considering that it is difficult to iden-
tify the individual impact of clinical factors on early-term 
events after AMI [17]. Thus, we evaluated the association 
between obesity and 2-year mortality in stabilized dia-
betic patients after AMI in the Korean population.
Methods
Subjects and study design
This is a prospective, multicenter, observational study of 
clinical outcomes following AMI in patients with type 2 
DM included in the DIabetic Acute Myocardial Infarc-
tiON Disease (DIAMOND) registry in Korea between 
April 2010 and June 2012. Initially, 1192 consecutive 
patients with type 2 DM who presented with ST-eleva-
tion myocardial infarction (STEMI) or non ST-elevation 
myocardial infarction (NSTEMI) were enrolled from 22 
university or tertiary hospitals that voluntarily partici-
pated in this study and were evenly distributed through-
out South Korea. All participants had: (a) age ≥45 years; 
(b) documented STEMI or NSTEMI by an elevated cre-
atine kinase-MB fraction (CK-MB) (exceeding 3 times 
upper limit of normal) and cardiac troponin-I level 
(exceeding upper normal limit); and (c) angiographically 
confirmed significant coronary stenosis (≥50  % luminal 
stenosis) with intracoronary filling defect or haziness 
suggesting coronary thrombus/vulnerable plaque, or cor-
onary spasm induced acute myocardial infarction defined 
by an elevated cardiac enzymes without significant steno-
sis. Type 2 DM was diagnosed by fasting plasma glucose 
level on two separate occasions ≥126 mg/dL or a random 
plasma glucose level ≥200 mg/dL or 2-h plasma glucose 
post 75 g dextrose load done on two separate occasions 
≥200  mg/dL, or previously diagnosed DM by taking 
oral hypoglycemic agents or using insulin. The duration 
of DM was defined as the time elapsed since a physician 
diagnosed the diabetic condition. BMI was calculated 
as weight (kg)/height (m2), and obesity was defined as a 
BMI of ≥25  kg/m2. Stabilized patients with AMI were 
defined as those who did not have any clinical events 
within 1  month after the initial presentation of AMI. 
Among these patients, 67 patients who died in hospital 
during admission or did not undergo follow-up within 
1 month after discharge were excluded from the present 
study. Finally, 1125 diabetic patients with AMI who did 
not have any events within 1  month were enrolled for 
evaluation of cardiac and all-cause mortality according to 
obesity status.
Percutaneous coronary intervention (PCI) was performed 
by stenting (stent type and glycoprotein IIb/IIIa receptor 
blocker use at operator’s discretion) using standard tech-
nique via femoral or radial approach after a loading dose of 
aspirin 100–200 mg and clopidogrel 300–600 mg followed 
by a daily dose of aspirin 100  mg and clopidogrel 75  mg, 
and an intravenous bolus dose of heparin (50–100  U/kg) 
and thereafter 100 U/kg as needed to maintain an activated 
clotting time of >250 s during PCI. After the index proce-
dure, aspirin 100–200 mg and clopidogrel 75 mg daily were 
prescribed for at least 12  months in patients treated with 
drug-eluting stent, as possible. All patients continued taking 
beta-blockers, angiotensin-converting enzyme inhibitors 
(ACEI) or angiotensin receptor blockers (ARB), and statins, 
whenever it was not contraindicated.
Coronary lesion morphology was classified using 
modified American College of Cardiology/American 
Heart Association criteria [18]. Thrombolysis in myocar-
dial infarction (TIMI) score was used to determine the 
degree of coronary flow before and after the procedure 
[19]. Multivessel disease was defined as the presence of 
other lesions with ≥50  % stenosis in the non-infarct 
related coronary artery. Hypertension was defined as sys-
tolic blood pressure ≥140 mmHg and/or diastolic blood 
pressure ≥90 mmHg or treatment with antihypertensive 
agents. Dyslipidemia was defined as total cholesterol 
≥240  mg/dL, low-density lipoprotein cholesterol (LDL) 
≥130 mg/dL, high-density lipoprotein cholesterol (HDL) 
≤40  mg/dL, triglyceride ≥150  mg/dL and/or treatment 
with lipid lowering agents. Transthoracic echocardiogra-
phy was performed to assess the left ventricular ejection 
fraction (LVEF) using the modified Simpson’s bi-planar 
method. Chronic kidney disease (CKD) was defined as 
an estimated glomerular filtration rate (eGFR) <60  mL/
min/1.73 m2 calculated by means of the modification of 
diet in renal disease formula [20]. The study outcomes 
were the occurrence of cardiac and all-cause death during 
2-year follow-up. All death was considered cardiac unless 
there was a clear non-cardiac cause. According to the 
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follow-up protocol, all patients were contacted at 1, 6, 12, 
and 24 months after the index procedures; if the patient 
did not attend a scheduled visit, outcome variables were 
obtained by telephone. The protocol of this study was 
approved by the appropriate Institutional Review Board/
Ethical Committee of the respective clinical site, and 
informed consent was obtained from all participants.
Statistical analysis
Clinical and biochemical characteristics are shown 
according to the presence of obesity. Values are 
expressed as mean ±  SD for continuous variables and 
numbers and percentages for categorical variables. 
Continuous variables were compared using Student’s t 
test, and categorical variables were compared using the 
χ2 test or Fisher’s exact test, as appropriate. Kaplan–
Meier survival analysis was performed for the cumula-
tive occurrence of cardiac death and all-cause death. 
Comparisons between groups were performed using the 
log-rank test. Univariate and multivariate Cox hazard 
regression analyses were performed to identify the asso-
ciation between obesity and cardiac and all-cause death. 
Variables entered into the univariate analysis were 
selected focusing on traditional CV risk factors, proce-
dural factors, the control status of hyperglycemia before 
AMI, and established clinical factors for mortality after 
AMI. Thus, univariate analysis included the following 
variables: old age (≥65 years), male gender, previous MI, 
hypertension, dyslipidemia, multivessel disease, stent 
diameter ≤2.75  mm, stent length ≥28  mm, HbA1c, 
CKD, LVEF <35  %, and obesity. Variables with P  <  0.1 
in the univariate analysis were entered into the multi-
variate Cox hazard regression analysis. The assumption 
of proportional hazards for the covariates included in 
the regression models was constant regardless of time, 
without significant interaction among them. SPSS sta-
tistical software version 20.0 (SPSS, Inc., Chicago, IL, 
USA) was used for all statistical analyses. Values of 
P < 0.05 were considered statistically significant.
Results
The clinical characteristics of the 1125 participants 
(age, 65  ±  10  years; 66  % men) in this study are pre-
sented in Table  1. Overall, the mean duration of DM 
was 10.9  ±  8.5  years, mean hemoglobin A1c (HbA1c) 
level was 7.8 ± 1.5 %, and mean BMI was 24.1 ± 3.0 kg/
m2 in the present study. The prevalence of obesity was 
38  %, and the majority of participants therefore were 
non-obese. The incidence of BMI <18.5 kg/m2 and BMI 
≥30 kg/m2 was only 2.2 and 3.6 %, respectively.
The distributions of baseline characteristics did not 
differ between obese and non-obese diabetics, except 
for those of age, duration of DM, and the incidence of 
CKD and insulin use which were significantly higher in 
non-obese DM patients, while obese DM patients had 
higher incidence of dyslipidemia and higher LVEF after 
Table 1 Clinical characteristics
ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin receptor 
blocker, BMI body mass index, CKD chronic kidney disease, CK-MB creatine 
kinase-MB, DM diabetes mellitus, eGFR estimated glomerular filtration rate, 
HbA1c hemoglobin A1c, HDL high density lipoprotein, hs-CRP high sensitivity 
C-reactive protein, LDL low density lipoprotein, LVEF left ventricular ejection 






Age, years 63 ± 10 66 ± 10 <0.001
Male 283 (66) 457 (66) 0.783
BMI, kg/m2 27.1 ± 2.0 22.3 ± 1.8 <0.001
Co‑existing conditions
 Hypertension 294 (69) 448 (64) 0.109
 Dyslipidemia 134 (31) 169 (24) 0.009
 CKD 110 (26) 232 (33) 0.008
 Previous MI 22 (5) 39 (6) 0.754
Smoking 143 (34) 229 (33) 0.814
STEMI 204 (48) 326 (47) 0.727
LVEF 53 ± 11 50 ± 12 <0.001
Systolic blood pressure, 
mmHg
130 ± 28 130 ± 28 0.851
Diastolic blood pressure, 
mmHg
78 ± 17 76 ± 16 0.116
eGFR, mL/min/1.73 m2 76 ± 29 72 ± 33 0.105
DM duration, years 9.8 ± 8.2 11.5 ± 8.5 0.003
Laboratory
 Total cholesterol, mg/dL 178 ± 46 170 ± 46 0.004
 Triglyceride, mg/dL 146 ± 98 131 ± 100 0.022
 LDL, mg/dL 109 ± 40 101 ± 41 0.002
 HDL, mg/dL 44 ± 28 44 ± 17 0.988
 Creatinine, mg/dL 1.2 ± 1.3 1.3 ± 1.4 0.130
 HbA1c, % 7.8 ± 1.4 7.9 ± 1.6 0.370
 hs‑CRP, mg/dL 4.6 ± 15.9 6.9 ± 23.9 0.081
 NT‑ProBNP, pg/mL 2836 ± 7592 4040 ± 9074 0.096
 Peak CK‑MB, ng/mL 82 ± 114 83 ± 137 0.880
 Troponin‑I, ng/mL 29 ± 62 31 ± 59 0.637
Medication at discharge, n (%)
 Aspirin 423 (99) 683 (98) 0.126
 Clopidogrel 409 (96) 661 (95) 0.413
 Cilostazol 83 (19) 131 (19) 0.781
 Beta blocker 364 (85) 591 (85) 0.794
 ACEI/ARB 355 (83) 586 (84) 0.720
 Statin 365 (86) 572 (82) 0.123
 Nitrate 111 (26) 205 (29) 0.222
 Nicorandil 77 (18) 149 (21) 0.178
 Insulin 51 (12) 119 (17) 0.020
2‑year clinical outcomes, n (%)
 Cardiac death 3 (0.7) 25 (3.6) 0.003
 All‑cause death 8 (1.9) 36 (5.2) 0.006
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AMI (Table 1). As shown in Table 2, there were no sig-
nificant differences in angiographic and procedural 
characteristics, except for significantly larger stent diam-
eter in obese vs. non-obese DM patients (3.18 ± 0.46 vs 
3.07 ± 0.43 mm, P < 0.001).
During 2-year follow-up period, a total of 28 cardiac 
deaths and 44 all-cause deaths occurred. The occurrence 
of cardiac death and all-cause death was significantly 
lower in diabetic patients with than without obesity (car-
diac death: 0.7 vs. 3.6 %, P =  0.003; all-cause death: 1.9 
vs. 5.2  %, P  =  0.006) (Table  1). Kaplan–Meier survival 
analysis revealed that the cumulative incidence of car-
diac death (P  =  0.002) and all-cause death (P  =  0.004) 
was lower in diabetic patients with obesity than in those 
without obesity (Fig. 1a, b). Kaplan–Meier survival analy-
sis revealed consistent result after excluding underweight 
patients with BMI <18.5 kg/m2 (Additional file 1: Figure 
S1, A and B).
Cox hazard regression models were performed to 
identify the determinants of cardiac and all-cause 
death in stabilized DM patients (Table  3). Both uni-
variate and multivariate Cox hazard regression analy-
ses adjusted for the respective confounders showed 
that obesity was associated with decreased risk of both 
cardiac [HR, 0.18 (95 % CI 0.06–0.60), P = 0.005; and 
0.24 (0.07–0.78), P = 0.018, respectively] and all-cause 
death [0.34 (0.16–0.73), P  =  0.005; and 0.44 (0.20–
0.95), P = 0.038]. In terms of confounders, in univariate 
Cox hazard regression analysis, age ≥65  years, CKD, 
and LVEF <35  % were significantly associated with 
increased risk of cardiac and all-cause death, while pre-
vious MI was associated with cardiac death. In multi-
variate Cox hazard regression analysis, CKD and LVEF 
<35  % were associated with increased risk of cardiac 
and all-cause death, and age ≥65  years with all-cause 
death.
Discussion
The main findings of the present analysis of the DIA-
MOND registry investigating the long-term clinical 
outcomes after contemporary treatment in stabilized 
diabetic patients with AMI in the Korean population are: 
(1) the majority of Korean diabetic patients with AMI are 
non-obese; (2) obesity is associated with decreased car-
diac and all-cause mortality after adjusting for confound-
ing clinical factors.
It is well known that obesity is strongly associated 
with an increased risk of CV mortality. Song et  al. [21] 
reported that higher CV mortality was observed in men 
compared with women across categories of anthro-
pometric measures of obesity, and the gender differ-
ence was attenuated in obese subjects. Novo et  al. [22] 
reported that subclinical atherosclerosis, especially if it 
Table 2 Angiographic and procedural characteristics
DES drug-eluting stent, LAD left anterior descending artery, LM left main 






Target vessel of LAD 209 (49) 355 (51) 0.533
Target vessel of LM 11 (3) 17 (2) 0.883
Multivessel disease 254 (60) 414 (59) 0.954
Type B2/C lesion 340 (82) 543 (83) 0.850
Pre‑PCI TIMI 0 173 (42) 260 (40) 0.465
Post‑PCI TIMI 2/3 400 (97) 639 (97) 0.592
Use of DES 341 (93) 540 (93) 0.684
Stent diameter, mm 3.18 ± 0.46 3.07 ± 0.43 <0.001
Stent length, mm 25.4 ± 9.6 24.8 ± 7.9 0.324
Number of implanted stents 1.6 ± 0.9 1.5 ± 0.8 0.703
Fig. 1 Kaplan–Meier analysis of a cumulative cardiac death‑free survival and b cumulative all‑cause death‑free survival according to obesity pres‑
ence among all participants
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was associated with metabolic syndrome (MetS) which 
has central obesity as its major characteristic, leads to an 
increased risk of CV mortality. These studies were per-
formed in the general population without consideration 
of major CV events such as AMI. In contrast, several 
recent studies reported the phenomenon of obesity para-
dox, i.e. long-term mortality appearing to be significantly 
lower among obese than non-obese patients after the 
event of AMI, albeit with different independent predic-
tive value of obesity for long-term mortality after adjust-
ing for confounding factors [23, 24]. There is a paucity of 
data on whether this phenomenon is observed in patients 
with DM, which is considered a coronary artery disease 
risk-equivalent in clinical practice [25].
Both a deterioration of insulin secretion and an aggra-
vation of insulin resistance are two pivotal defects in the 
pathogenesis of DM [26, 27]. It is obvious that obesity is 
one of the major factors for insulin resistance, but the 
criterion and prevalence of obesity differ according to 
ethnicity. Moreover, the clinical features of the develop-
ment of type 2 DM in Asia are somewhat different from 
those in other parts of the world, with DM developing 
at a younger age and in subjects with much lower BMI 
despite the substantial increases in the prevalence of obe-
sity and type 2 DM in Asia [14]. In Korea, previous stud-
ies reported that 65 % of diabetic subjects are non-obese 
and that impaired insulin secretion is more prominent 
than insulin resistance in the pathogenesis of type 2 DM, 
even in the status of impaired glucose tolerance [28–30]. 
In the present study, the majority of diabetic patients, 
approximately 62  %, also was non-obese. This value is 
very similar compared to the previous studies although 
our study was performed in diabetic patients after the 
event of AMI.
Although the phenomenon of the obesity paradox, i.e., 
obesity appearing to be associated with improved survival 
in patients with AMI, has been replicated [5–9], there is a 
paucity of data on the association between obesity and CV 
mortality in diabetic patients with AMI, and it is uncer-
tain whether this effect persists in stabilized patients after 
the event of AMI, which warrants investigation because 
the confounding relationships among multiple clinical 
factors may be able to simultaneously influence develop-
ment of early-term events [17]. A recent study reported 
a strong protective effect of overweight or obesity on 
all-cause mortality in AMI patients without DM, but the 
effect was not found among those with DM [31]. How-
ever, in the latter German population-based AMI registry 
study the prevalence of overweight or obesity defined as a 
BMI ≥25 kg/m2 was up to 81 % among diabetic patients. 
In particular, the prevalence of obesity defined as a BMI 
≥30 kg/m2 was almost 38 % among diabetic patients. In 
contrast, the prevalence of BMI ≥30 kg/m2 was only 3.6 % 
(41 patients) in the present study, which might have con-
tributed to the different results obtained.
The exact mechanism by which obesity improves sur-
vival after the event of AMI is unknown. However, one 
potential explanation is that obese patients may have 
less severe left ventricular systolic dysfunction after the 
event of AMI. In experimental data, using a diet-induced 
obesity model, Poncelas et  al. [32] suggested the ben-
eficial effect of increased insulin signaling as the mecha-
nism underlying the obesity paradox, and Salie et al. [33] 
reported that obesity-inducing diets appeared to have a 
Table 3 Cox hazard regression models to identify the independent determinants for cardiac and all-cause death
CI confidence interval, CKD chronic kidney disease, HbA1c hemoglobin A1c, HR hazard ratio, LVEF left ventricular ejection fraction, MI myocardial infarction
Cardiac death All-cause death
Univariate Multivariate Univariate Multivariate
HR (95 % CI) P HR (95 % CI) P HR (95 % CI) P HR (95 % CI) P
Age ≥65 years 4.52 (1.72–11.88) 0.002 2.65 (0.98–7.15) 0.055 3.99 (1.91–8.31) <0.001 2.58 (1.09–6.10) 0.031
Male 0.68 (0.32–1.44) 0.317 0.56 (0.31–1.02) 0.056 0.63 (0.34–1.19) 0.157
Previous MI 3.07 (1.07–8.85) 0.038 2.37 (0.81–6.94) 0.114 2.41 (0.95–6.11) 0.065 1.80 (0.70–4.63) 0.227
Hypertension 1.94 (0.79–4.79) 0.150 1.98 (0.95–4.13) 0.069 1.35 (0.60–3.00) 0.466
Dyslipidemia 1.33 (0.60–2.94) 0.481 1.21 (0.63–2.32) 0.563
CKD 3.62 (1.70–7.73) 0.001 2.47 (1.11–5.54) 0.028 4.38 (2.34–8.21) <0.001 3.10 (1.56–6.17) 0.001
Multivessel disease 1.19 (0.55–2.57) 0.663 1.08 (0.59–1.99) 0.801
HbA1c, % 1.17 (0.90–1.52) 0.245 1.01 (0.80–1.29) 0.920
Stent diameter ≤2.75 mm 0.87 (0.28–2.75) 0.817 0.71 (0.29–1.76) 0.456
Stent length ≥28 mm 1.62 (0.59–4.49) 0.350 1.86 (0.88–3.95) 0.105
LVEF <35 % 6.09 (2.79–13.30) <0.001 4.18 (1.90–9.23) <0.001 4.77 (2.47–9.21) <0.001 3.35 (1.72–6.53) <0.001
Obesity 0.18 (0.06–0.60) 0.005 0.24 (0.07–0.78) 0.018 0.34 (0.16–0.73) 0.005 0.44 (0.20–0.95) 0.038
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cardioprotective effect against ischemia or reperfusion 
damage. In clinical data, Lundergan et  al. [34] reported 
that high BMI was associated with an increased effect of 
preservation of LVEF and improved 30-day survival in 
patients with AMI. Sohn et al. [35] recently reported that 
obesity is independently associated with smaller infarct 
size which was identified using contrast-enhanced mag-
netic resonance imaging in Korean patients undergoing 
primary PCI for STEMI. In the present study, diabetic 
patients with obesity had significantly higher LVEF com-
pared to those without obesity after AMI. In addition, 
the incidence of LVEF <35  % that was independently 
associated with both cardiac and all-cause death was sig-
nificantly lower among diabetic patients with than those 
without obesity.
Several previous studies investigated the association 
between obesity and coronary atherosclerosis using coro-
nary computed tomographic angiography. Labounty et al. 
[36] reported that an increased BMI was associated with a 
greater prevalence, extent, and severity of coronary artery 
disease (CAD). Dores et al. [37] reported that obesity was 
associated with the presence of CAD, but it was not corre-
lated with the severity of CAD in subjects with suspected 
CAD. However, these studies were based on Western 
populations and evaluated the relationship between BMI 
and coronary atherosclerosis without the consideration 
of diabetic status. Recently, Won et al. [38] reported that 
DM was strongly associated with coronary parameters 
including any plaque, obstructive plaque, and coronary 
artery calcium score (CACS) >100 in a Korean popula-
tion. According to this study, the prevalence of obesity 
was significantly higher in diabetic subjects than in non-
diabetic subjects but the majority of diabetic patients 
were non-obese. Obesity was independently associated 
with the presence of any plaque and CACS >100 in non-
diabetic subjects, but it was not associated with any cor-
onary parameters in established diabetic subjects. These 
results may imply that obesity contributes to the develop-
ment of DM but it is not a useful predictor for the pres-
ence and severity of CAD in established diabetic subjects 
in a Korean population. Further investigation to identify 
the association between obesity and major CV complica-
tions may be necessary in Asian diabetic patients.
The prevalence of obesity which is significantly associ-
ated with dyslipidemia, type 2 DM, and CV disease has 
increased worldwide. Although BMI is the most com-
monly used anthropometric tool to assess obesity status, 
BMI which might not be the ideal measure to discrimi-
nate between fat and lean body mass. Considering that 
recent studies emphasized the quality or function of 
adipose tissue compared with its amount with respect 
to CV disease [39] and the optimal treatment for athero-
genic dyslipidemia in association with obesity [40], it is 
necessary to evaluate the phenomenon of obesity para-
dox focusing on these issues. Additionally, further study 
is warranted to assess whether the phenomenon of obe-
sity paradox results from a statistical artifact associated 
with collider stratification bias [41].
The present study has some limitations. First, we identi-
fied an association between obesity and survival but did 
not present the range of BMI over which it held, which 
was difficult to determine because only 41 (3.6 %) of our 
diabetic patients had a BMI ≥30  kg/m2. The latter pro-
portion was very small compared to those reported in 
other studies investigating the obesity paradox phenom-
enon, which might be related to the explicitly different 
characteristics of DM in the Asian population. Second, 
we only used BMI which might not be the ideal measure 
to discriminate between fat and lean body mass to iden-
tify obesity status; however, a previous study reported 
that BMI was significantly associated with abdominal fat 
and waist circumference in Korean subjects [42]. Third, 
the present study might have underestimated the risk of 
mortality because clinical events are likely to occur in the 
acute stage after AMI presentation, especially for high-
risk patients. However, this study was performed to focus 
on excluding confounding impact of multiple factors dur-
ing the early stage after the event of AMI. Finally, we did 
not control for the stent type which may have influenced 
study results. Despite its limitations, the present study is 
unique in that it identified the obesity paradox in stabi-
lized diabetic patients after the event of AMI in an Asian 
population. Considering the different clinical features of 
diabetic patients in Asian compared to Western popula-
tions, the results of this study may provide valuable infor-
mation on the association between obesity and prognosis 
after the event of AMI in Asian diabetic patients.
Conclusion
In a Korean population of stabilized DM patients after 
the event of AMI, cardiac and all-cause mortality 
appeared to be higher in non-obese than obese patients. 
Obesity was significantly associated with decreased risk 
for cardiac and all-cause death after adjusting for con-
founding risk factors.
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protein; HR: hazard ratio; hs‑CRP: high sensitivity C‑reactive protein; LAD: left 
anterior descending artery; LDL: low‑density lipoprotein; LM: left main coro‑
nary artery; LVEF: left ventricular ejection fraction; MetS: metabolic syndrome; 
MI: myocardial infarction; NSTEMI: non ST‑elevation myocardial infarction; 
NT‑ProBNP: N‑terminal prohormone of brain natriuretic peptide; PCI: percuta‑
neous coronary intervention; QCA: quantitative coronary angiography; STEMI: 
ST‑elevation myocardial infarction; TIMI: thrombolysis in myocardial infarction.
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